Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study
- Macaluso F. S.
- Principi M.
- Facciotti F.
- Contaldo A.
- Todeschini A.
- Saibeni S.
- Bezzio C.
- Castiglione F.
- Nardone O. M.
- Spagnuolo R.
- Fantini M. C.
- Riguccio G.
- Caprioli F.
- Vigano C.
- Felice C.
- Fiorino G.
- Correale C.
- Bodini G.
- Milla M.
- Scardino G.
- Vernero M.
- Desideri F.
- Mannino M.
- Rizzo G.
- Orlando A.
- Amato A.
- Ascolani M.
- Calabrese G.
- Casa A.
- Comberlato M.
- Conforti F. S.
- De Bona M.
- Demarzo M. G.
- Doldo P.
- Dragoni G.
- Furfaro F.
- Mulinacci G.
- Olmo O.
- O'Sed N. P.
- Paba S.
- Radice S.
- Renna S.
- Ribaldone D. G.
- Rizzuto G.
DOIAbstract
Background: Patients on immunosuppressive drugs have been excluded from COVID-19 vaccines trials, creating concerns regarding their efficacy. Aims: To explore the humoral response to COVID-19 vaccines in patients with inflammatory bowel disease (IBD) Methods: Effectiveness and Safety of COVID-19 Vaccine in Patients with Inflammatory Bowel Disease (IBD) Treated with Immunomodulatory or Biological Drugs (ESCAPE-IBD) is a prospective, multicentre study promoted by the Italian Group for the study of Inflammatory Bowel Disease. We present data on serological response eight weeks after the second dose of COVID-19 vaccination in IBD patients and healthy controls (HCs). Results: 1076 patients with IBD and 1126 HCs were analyzed. Seropositivity for ...
Add to ORKG